NCT07177469 - UBT251 Injection Phase II Study (Overweight or Obesity) | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Obesity &Amp; Overweight

Interventions

DRUG

UBT251 Injection 2.0 mg and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

DRUG

UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

DRUG

UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

DRUG

UBT251 Injection 6.0 mg and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

Trial Locations (1)

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

The United Bio-Technology (Hengqin) Co., Ltd.

INDUSTRY